adobe indesign cs3 cheap buy pdf converter cheap word 2010 cost of final cut pro express best price revit architecture cheap reason 4 best price 2008 server cheap photoshop 8 buy indesign cs4 windows norton ghost 12 price best price office 2007 small business upgrade buy contribute cs4 buy encarta kids 2009 price of microsoft office 2010 in india best price photoshop cs5 upgrade final cut express 4 price buy reason 4.0 1 best buy photoshop elements 6 purchase adobe professional cheap excel 2003 purchase flash cs6 buy windows xp professional full version buy reason 4.0 price buying lightroom 3 upgrade best price adobe cs4 design premium full buy cs3 adobe best price ilife 11 rosetta stone at costco buy nero software used adobe photoshop software

Hypersensitivity Reactions to Erbitux Caused by Tick Bites.

Fri, Jul 1, 2011

Oral Cancer News

Source: Gastroenterology & Endoscopy News

Hypersensitivity reactions to cetuximab (Erbitux, ImClone Systems/Bristol-Myers Squibb), a monoclonal antibody approved for use in colorectal cancer, are not caused by the drug itself but by preexisting immunoglobulin E (IgE) antibodies that may result from tick bites, researchers have found.

Cetuximab, like other monoclonal antibodies, is generally associated with a low rate of severe anaphylactic reactions (3%), but reports of such reactions to cetuximab have recently increased in southeastern states, including Tennessee and North Carolina. Researchers found IgE antibodies in pretreatment samples of 68% of patients allergic to cetuximab that were specific for galactose-α-1,3-galactose, an oligosaccharide present on the Fab portion of the cetuximab heavy chain.

The authors noted that rates of anaphylactic reaction may be lower with other monoclonal antibodies because cetuximab is produced in the mouse cell line SP2/0, which expresses this oligosaccharide, whereas most other monoclonal antibodies are produced in a Chinese hamster ovary cell line that does not express this molecule.

Theories to explain the increased hypersensitivity of patients in the Southeast initially centered on exposure to worms, such as roundworms or tapeworms. However, researchers now believe the true culprit may be ticks, whose bites have resulted in the development of this type of IgE antibody.

Pretreatment samples were obtained from 76 people treated with cetuximab at centers mainly in Tennessee, Arkansas and North Carolina; the control group included 72 people in Tennessee, 49 patients with cancer in northern California and 341 women in Boston. Of the patients on cetuximab, 25 had an allergic reaction to the drug, and IgE antibodies were found in pretreatment samples from 17 (68%) of them, whereas IgE antibodies were found in the pretreatment sample of only 1 (2%) of the 51 people on cetuximab who did not have an allergic reaction (P<0.001).

The authors believe it may be possible to test patients to determine whether they would be at greater risk for anaphylaxis with cetuximab. The ImmunoCAP assay used in the study to detect IgE antibodies has a sensitivity of 68% and a specificity of 98% for any hypersensitivity reaction; for especially severe reactions, its sensitivity was 92% and its specificity was 90%. However, the assay is in development and not currently available commercially.

—Based on Chung CH et al (N Engl J Med 2008;358:1109-1117)

This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Print Friendly
Be Sociable, Share!
, , , , , ,

Leave a Reply

You must be logged in to post a comment.